




PROGRESSIVE'S EVENING STROLL

DATE: 22 June, 2021

Market Snapshot:

Strong follow-through pushed the Index higher after a firm opening but weakness in banking stocks dragged the Index lower to end the session at 15,772.75 with the gains of 26.25 points. On sector-wise performance, Auto was the top gainer followed by IT and Metal while BankNifty ended the session as a major laggard.

HOW THE DAY TRENDED



INDICES			
Index	Close	Points	% chg
Sensex	52588.71	14.25	0.03
Nifty	15772.75	26.25	0.17
Nifty Midcap 100	26732.75	27.55	0.10
Nifty Small Cap 100	9686.30	50.25	0.52

MARKET ACTION		
A/D	BSE	NSE
Advances	2027	1195
Declines	1211	745
Unchanged	125	321
A/D TREND	BULL	BULL

SECTORAL GAINERS / LOSERS			
Sectors	Close	Points	% chg
NIFTY AUTO	10540.45	139.30	1.34
NIFTY IT	28523.55	156.55	0.55
NIFTY METAL	5119.40	14.20	0.28
NIFTY BANK	34745.00	(126.30)	(0.36)

NIFTY TOP GAINERS / LOSERS			
Gainers	%chg	Losers	% chg
MARUTI	5.30	ASIAN PAINTS	(1.88)
UPL	3.92	BAJAJ FINANCE	(1.62)
SHREE CEMENTS	3.59	NESTLEIND	(1.20)
WIPRO	2.66	HUL	(0.96)

INDICES LEVELS FOR June 23,2021

Nifty (future)	
Resistance	15,900
Support	15,540

Bank Nifty (future)	
Resistance	35,060
Support	34,100





KEY TAKEAWAYS OF THE DAY

◆ **KPIT Technologies to acquire controlling stake in PathPartner Technology:**

KPIT Technologies announced the signing of a definitive agreement to acquire a controlling stake in PathPartner Technology. PathPartner is a specialist design service and solution provider of operating system software and low-level software for Automotive, Camera, Radar, and Multimedia devices. The deal is subject to customary closing conditions and is expected to get closed in Q2FY22. KPIT will initially purchase 60% for a consideration of Rs89cr, and the balance stake is proposed to be acquired over a period of 2 years against defined growth targets. The total consideration for 100% will not exceed Rs191cr.

◆ **Sharp recovery: Unlock 2.0 sparks 15% growth in FMCG sales:**

India's fast-moving client items (FMCG) market has recovered sharply after a number of states eased restrictions because the second Covid-19 wave abated, serving to the market broaden 15% in the primary two weeks of June from the month earlier. Sales had been additionally boosted by a 28% improve in the variety of kirana retailers that reopened this month, a distinction from the final two months, when the native grocer depend fell sharply, in response to the most recent examine by Bizom, which tracks sales of 7.5million retail shops throughout the nation.

◆ **Adani Transmission seeks shareholders' approval to raise Rs 2,500cr:**

Adani Transmission will seek shareholders nod to raise up to Rs2,500cr in one or more tranches through the issuance of equity shares, securities, debentures etc. The company proposes to have the flexibility to infuse additional capital, to tap the capital markets and to raise additional long term resources, if necessary to sustain rapid growth in the business, for business expansion and to improve the financial leveraging strength of the company.

◆ **Muthoot Fincorp acquires 54% stake in Paymatrix:**

Muthoot Fincorp has picked up 54% stake in Hyderabad-based fintech startup Paymatrix by buying out existing investors as part of its added focus on digital payments segment. Investment in Paymatrix will help extend the existing lending business by giving a competitive edge in terms of expanding the product offerings and make a foray into new markets and new customer segments. Paymatrix was set up in 2016 with a vision to streamline property rent payments and rent collections for tenants and landlords.

◆ **Sun Pharma announces settlement of patent litigation for Generic Revlimid (lenalidomide) in US:**

Sun Pharma announced that it has reached an agreement with Celgene a wholly-owned subsidiary of Bristol Myers Squibb, to resolve the patent litigation regarding submission of an ANDA for a generic version of Revlimid (lenalidomide capsules) in the US. Pursuant to the terms of the settlement, Celgene will grant Sun Pharma a license to Celgene's patents required to manufacture and sell (subject to USFDA approval) certain limited quantity of generic lenalidomide capsules in the US beginning on a confidential date that is sometime after March 2022. In addition, the license will also allow Sun Pharma to manufacture and sell an unlimited quantity of generic lenalidomide capsules in the US beginning January 31, 2026.

Source: Media Reports

